9877 Stock Overview
Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of invasive interventional therapies for structural heart diseases in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Jenscare Scientific Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.73 |
| 52 Week High | HK$45.00 |
| 52 Week Low | HK$3.17 |
| Beta | 0 |
| 1 Month Change | -43.08% |
| 3 Month Change | -67.47% |
| 1 Year Change | -87.55% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -83.26% |
Recent News & Updates
Shareholder Returns
| 9877 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 22.5% | 3.5% | 3.5% |
| 1Y | -87.6% | -49.9% | -9.9% |
Return vs Industry: 9877 underperformed the Hong Kong Medical Equipment industry which returned -49.9% over the past year.
Return vs Market: 9877 underperformed the Hong Kong Market which returned -9.9% over the past year.
Price Volatility
| 9877 volatility | |
|---|---|
| 9877 Average Weekly Movement | 17.3% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.7% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 9877's share price has been volatile over the past 3 months.
Volatility Over Time: 9877's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 376 | Shiwen Lv | www.jenscare.com |
Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of invasive interventional therapies for structural heart diseases in the People’s Republic of China. The company offers LuX-Valve, a transcatheter tricuspid valve replacement (TTVR) product candidate for the treatment of severe tricuspid regurgitation and high surgical risk; and Ken-Valve, a transcatheter aortic valve replacement product candidate for the treatment of severe aortic regurgitation or combined with aortic stenosis. Its products have applications in the treatment of structural heart diseases, including tricuspid valve diseases, aortic valve diseases, mitral valve diseases, and heart failure.
Jenscare Scientific Co., Ltd. Fundamentals Summary
| 9877 fundamental statistics | |
|---|---|
| Market cap | HK$1.75b |
| Earnings (TTM) | -HK$401.63m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.9x
P/E RatioIs 9877 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9877 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥371.74m |
| Earnings | -CN¥371.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.89 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 3.3% |
How did 9877 perform over the long term?
See historical performance and comparison